Form 4: Neurogene Director Keith Woods Granted Stock Options

Neurogene Inc. Director Keith Woods was granted 12,050 non-qualified stock options with an exercise price of $17.64, vesting monthly over one year.

Summary

• Keith Woods, a Director of Neurogene Inc. (NGNE), was granted 12,050 non-qualified stock options.
• The options have an exercise price of $17.64 per share.
• The transaction date for the grant was February 20, 2026.
• The options begin vesting as to 1/12 of the total shares monthly starting March 20, 2026.
• The options will be fully vested on February 20, 2027, contingent on Mr. Woods' continued service to the Issuer.
• The expiration date for these options is February 20, 2036.
• Following this transaction, Mr. Woods beneficially owns 12,050 derivative securities directly.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, as it signifies continued alignment between a key director and shareholder interests, which is generally favorable for corporate governance and long-term strategy.

Positives

• The grant of stock options aligns the interests of Director Keith Woods with those of shareholders, incentivizing long-term company performance.
• This is a standard form of compensation for directors, reflecting ongoing commitment to the company.

Negatives

• The exercise of these options in the future could lead to a minor dilutive effect on existing shareholders, although this is a common aspect of equity compensation plans.

Future Outlook

The vesting schedule of the stock options, extending to February 20, 2027, indicates an expectation of continued service from Director Keith Woods to Neurogene Inc. for the options to fully vest.

Industry Context

StockSavvy.ai notes that granting stock options to directors is a common practice across the biotechnology and pharmaceutical industries. This method of compensation is widely used to attract and retain experienced board members, ensuring their financial interests are tied to the company's long-term success and shareholder value creation.

Comparison to Industry Standards

• The grant of non-qualified stock options to a director is a standard compensation mechanism, comparable to practices at similar-sized biotech firms like Sarepta Therapeutics (SRPT) or Alnylam Pharmaceuticals (ALNY), which frequently use equity grants to incentivize leadership.
• The vesting schedule, typically over one to four years, is also consistent with industry benchmarks for aligning director incentives with company performance over a sustained period.

Related Party Transactions

• The grant of non-qualified stock options to Director Keith Woods by Neurogene Inc. constitutes a related party transaction, as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: Potential for increased alignment of director's interests with shareholder value, but also potential future dilution upon option exercise.
• Employees (Director): Provides a significant incentive for continued service and performance, linking personal financial success to company growth.

Next Steps

• Keith Woods must continue to provide service to Neurogene Inc. for the options to vest according to the monthly schedule.
• The options will become fully vested on February 20, 2027, assuming continued service.

Key Dates

Recommendation

This Form 4 filing reports a routine grant of stock options to a director, which is a standard compensation practice. While it indicates continued alignment of interests, it does not present new fundamental information that would warrant a change in an investor's existing position or outlook on Neurogene Inc. The transaction is expected and does not significantly alter the company's financial or strategic landscape.

Keywords

Neurogene Inc., NGNE, Keith Woods, Stock Options, Director Compensation, Insider Transaction, Equity Grant, SEC Form 4